no enhanced bioavailability vs epidylix though.....
so the animal studies didnt translate.
not the homerun we were looking for.
animal studies showed 1.5 -2 x bioavailability.
now we are highlighting its better than other australian products.. but no better in bioavilibility than market leader.
So whats our advantage? cheaper, easier dosing, capsule vs oil, preference from consumer? its not more effective dose for dose
- Forums
- ASX - By Stock
- Ann: EMD-RX5 demonstrates excellent safety and bioavailability
EMD
emyria limited
Add to My Watchlist
8.82%
!
3.7¢

no enhanced bioavailability vs epidylix though.....so the animal...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.7¢ |
Change
0.003(8.82%) |
Mkt cap ! $22.62M |
Open | High | Low | Value | Volume |
3.4¢ | 3.7¢ | 3.4¢ | $208.7K | 5.933M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 260004 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.7¢ | 171787 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 260004 | 0.036 |
4 | 1368713 | 0.035 |
2 | 310000 | 0.034 |
1 | 200000 | 0.033 |
3 | 430311 | 0.032 |
Price($) | Vol. | No. |
---|---|---|
0.037 | 171787 | 3 |
0.038 | 110307 | 3 |
0.039 | 108333 | 3 |
0.040 | 494999 | 4 |
0.044 | 21740 | 1 |
Last trade - 13.56pm 23/07/2025 (20 minute delay) ? |
Featured News
EMD (ASX) Chart |